|
|
Vaccine Detail
|
MAGE-A3-expressing Adenovirus Type 5 Vaccine |
| Vaccine Information |
- Vaccine Name: MAGE-A3-expressing Adenovirus Type 5 Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007540
- Type: Other
- Status: Clinical trial
- Host Species for Licensed Use: Human
- Host Species as Laboratory Animal Model: Human
- MAGEA3
gene engineering:
- Type: Recombinant protein preparation
- Description: (Pol et al., 2019)
- Detailed Gene Information: Click Here.
- Description: An oncolytic adenoviral vaccine composed of a replication-defective, E1- and E3-deleted adenovirus serotype 5 (Ad5) with a transgene encoding the human melanoma antigen A3 (MAGE-A3), with potential antineoplastic activity. Upon administration, MAGE-A3-expressing adenovirus type 5 vaccine selectively replicates in cancer cells and expresses MAGE-A3. This induces an immune response against tumor cells expressing the MAGE-A3 antigen, which leads to tumor cell death. The tumor-associated antigen MAGE-A3 is overexpressed by a variety of cancer cell types. (NCIT_C119614).
|
| Host Response |
|
|
| References |
NCIT_C119614: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C119614]
Pol et al., 2019: Pol JG, Acuna SA, Yadollahi B, Tang N, Stephenson KB, Atherton MJ, Hanwell D, El-Warrak A, Goldstein A, Moloo B, Turner PV, Lopez R, LaFrance S, Evelegh C, Denisova G, Parsons R, Millar J, Stoll G, Martin CG, Pomoransky J, Breitbach CJ, Bramson JL, Bell JC, Wan Y, Stojdl DF, Lichty BD, McCart JA. Preclinical evaluation of a MAGE-A3 vaccination utilizing the oncolytic Maraba virus currently in first-in-human trials. Oncoimmunology. 2019; 8(1); e1512329. [PubMed: 30546947].
|
|
